Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

549
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
549
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

311
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
311
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

236
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
236
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

485
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
485
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

276
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
276
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

229
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
229

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of Medicare Advantage Stars Measures: Impact on Kidney Care Quality and Future Opportunities.

Journal of the American Society of Nephrology : JASN·2026
Same author

Ovarian hyperstimulation syndrome with pleural effusion after unassisted pregnancy during a luteal-phase stimulation cycle.

F&S reports·2026
Same author

A Survey of Home Dialysis Competency, Exposure, and Barriers Among Nephrology Fellows in the United States.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same author

Impact of time to endovascular securement on outcomes in aneurysmal subarachnoid hemorrhage.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2026
Same author

A Multicenter Analysis of Baseline Patient-Reported Outcome Measures as Predictors of Progression From Spinal Cord Stimulator Trial to Implantation.

Neuromodulation : journal of the International Neuromodulation Society·2026
Same author

Assessment of the Modified Rankin Scale in Electronic Health Records With a Fine-Tuned Large Language Model: Development and Internal Validation.

JMIR AI·2026

Related Experiment Video

Updated: Sep 29, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.4K

Erenumab for episodic migraine.

Abhigyan Datta1, Sahil Gupta2, Shashi Maryala3

  • 1Maulana Azad Medical College, New Delhi, 110002, India.

Pain Management
|March 22, 2022
PubMed
Summary

Erenumab, a CGRP pathway monoclonal antibody, significantly reduces monthly migraine days for episodic migraine patients. It shows a favorable safety profile but faces cost limitations, requiring more real-world data.

Keywords:
AimovigCGRP antagonistsepisodic migraineerenumabheadachemigraine

More Related Videos

Modeling Neural Immune Signaling of Episodic and Chronic Migraine Using Spreading Depression In Vitro
16:13

Modeling Neural Immune Signaling of Episodic and Chronic Migraine Using Spreading Depression In Vitro

Published on: June 13, 2011

20.1K
Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture
09:06

Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture

Published on: December 22, 2016

9.7K

Related Experiment Videos

Last Updated: Sep 29, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.4K
Modeling Neural Immune Signaling of Episodic and Chronic Migraine Using Spreading Depression In Vitro
16:13

Modeling Neural Immune Signaling of Episodic and Chronic Migraine Using Spreading Depression In Vitro

Published on: June 13, 2011

20.1K
Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture
09:06

Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture

Published on: December 22, 2016

9.7K

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Migraine is a prevalent neurological disorder.
  • The calcitonin gene-related peptide (CGRP) pathway is a key target for migraine prevention.

Purpose of the Study:

  • To review erenumab, a monoclonal antibody targeting the CGRP pathway.
  • To assess the efficacy and safety of erenumab for episodic migraine prevention.

Main Methods:

  • Review of randomized controlled trials (RCTs) and post hoc analyses.
  • Evaluation of erenumab at 70 mg and 140 mg doses.

Main Results:

  • Erenumab demonstrated a statistically significant decrease in monthly migraine days over 9-12 weeks.
  • Long-term efficacy maintenance was observed in post hoc analyses.
  • Favorable safety profiles were reported for both 70 mg and 140 mg doses.

Conclusions:

  • Erenumab is effective for preventative treatment of episodic migraine.
  • High financial cost is a significant limitation.
  • Further long-term, real-world data are needed to fully establish its role in migraine management.